company

GoPath Launches ProstateNow for Hereditary Prostate Cancer Risk

 GoPath Launches ProstateNow for Hereditary Prostate Cancer Risk

GoPath Laboratories is pleased to announce the expansion of our GeneticsNowTM hereditary cancer testing series with the addition of our newest assay,  ProstateNowTM. This 14-gene panel was developed specifically to detect genetic mutations associated with inherited prostate cancer risk.
 
 GoPath Launches ProstateNow for Hereditary Prostate Cancer RiskProstateNowTM is an NGS-based (next-generation sequencing) assay that examines a variety of genes currently associated with hereditary prostate cancer. Genes included in this panel are: ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PMS2, PALB2, RAD51D and TP53.
 
The focus of hereditary cancer testing often has been on women with a family history of hereditary breast and ovarian cancers (HBOC). However, recent findings have indicated that genetic mutations associated with BRCA and Lynch syndrome can increase a man’s risk for developing prostate cancer. In fact, it is now believed that approximately 5-10% of all prostate cancers are inherited. ProstateNowTM can give men who have a family history of prostate and other hereditary cancers a risk prediction which can lead to earlier screenings and other preventive measures.
 
ProstateNowTM detects germline variants as well as duplication/deletion of most genes in the panel. We are constantly researching and adding new genes to our hereditary panels as their links to hereditary prostate cancer are discovered. ProstateNowTM also provides highly accurate results with a quick 10-14 day turnaround.
 
As part of our continuing efforts to make the hereditary testing process easy to understand for patients, we offer our free GeneticsNowTM guide to hereditary cancer testing for men and women. To receive one or more copies, please fill out our contact form or call us at 855.GOPATH9.